Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Contrast dye test reveals hidden kidney damage in ICU survivors

NCT ID NCT02961478

Knowledge-focused Sponsor: University Hospital, Angers Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 29, 2026 · Last updated Jun 30, 2026 · Updated 1 time

Summary

This study uses a dye called iohexol to measure how well the kidneys are working in patients leaving the intensive care unit after acute kidney failure. The goal is to find out how many patients still have reduced kidney function even though their standard blood tests look normal. The results could help doctors better understand who needs long-term follow-up for kidney health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
iohexol (Omnipaque)
What this could lead to
If successful, this could help doctors better predict long-term kidney recovery in ICU survivors and guide follow-up care.
What could go wrong
This is a measurement study, not a treatment. It may not change outcomes directly, and iohexol clearance is not a standard test in all hospitals.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

150 people

The number who actually took part.

Started

Feb 2017

Finished

Nov 2022

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * ICU stay \> 7 days * Having presented during the stay renal failure stage 2 or 3 Kidney Disease Improving Global Outcomes (KDIGO) * Steady improvement of renal function before the ICU discharge : * Creatinine before ICU discharge \<110 µmol / L for women, \<130 µmol / L for men * No recourse to extra renal purification * Change in creatinine levels (ΔCréatinine) less than 20% over two measures spaced 24 hours within 48 hours preceding the discharge * Expected discharge ICU within 48 hours : * Glasgow score \> 13 * Lack of mechanical ventilation except home Noninvasive Mechanical Ventilation (NiMV) * Lack of use of catecholamine * No contra-indication for discharge according to physician in charge of the patient * Informed consent signed by the patient, where not possible by the person of trust or the family if present. Written consent by the patient will be obtained as soon as deemed possible. Exclusion Criteria: * Iohexol administration within 48 hours preceding the potential inclusion (imaging examination with X-ray contrast medium injection) * Iohexol administration planned within 24 hours after potential inclusion in the study * Known medical history of immediate allergic or delayed skin allergic reaction to injection of iodinated contrast material or any serious doubt on this medical history * Patient receiving from extra renal purification during ICU discharge * Chronic renal disease known (creatinine\> 110 µmol / L for women,\> 130 µmol / L for men) or creatinine clearance estimated less than 60 mL / min * Pregnancy or breastfeeding women * Patient under guardianship or safeguard justice known at the time of inclusion * Patient limitation care * Person not affiliated or not the beneficiary of a social security scheme

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute renal failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acute kidney injury

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute renal failure

Contacts and locations

Locations

  • Hospital

    Le Mans, France

  • Hospital center

    Chartres, France

  • Jean Perrin Center

    Clermont-Ferrand, France

  • Saint-Louis Hospital APHP

    Paris, France

  • University Hospital

    Angers, France

  • University Hospital

    Poitiers, France

  • University Hospital

    Tours, France

  • University Hospital of Brest

    Brest, France

  • University Hospital of NIce

    Nice, France

  • University Hospital of Nantes

    Nantes, France

  • Vendée Department Hospital Center

    La Roche-sur-Yon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.